SCM
ALLO icon

Suvretta Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Suvretta Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-265,116
Closed -$3.96M – 92
2021
Q4 		$3.96M Buy
+265,116
New +$4.68M 0.08% 75
2021
Q1 		– Sell
-483,200
Closed -$12.2M – 107
2020
Q4 		$12.2M Buy
+483,200
New +$15.7M 0.17% 56

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Suvretta Capital Management's ALLO Position: Q1 2022 in Review

Suvretta Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 265,116 shares — an estimated $3.96M sold.

Suvretta Capital Management first reported a position in ALLO in Q4 2020 and held it in 2 quarters. The position peaked at $12.2M in Q4 2020. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

  • Suvretta Capital Management reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 265,116 Allogene Therapeutics shares in Q1 2022, an estimated $3.96M.
  • Suvretta Capital Management first reported a position in Allogene Therapeutics in Q4 2020 and held it in 2 quarters.
  • Suvretta Capital Management's Allogene Therapeutics position peaked at $12.2M in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.